Eris Lifesciences acquires trademark anti-diabetes drug Zomelis from Novartis for Indian market

Eris Lifesciences acquires trademark anti-diabetes drug Zomelis from Novartis for Indian market

Eris Lifesciences has announced that the company has acquired trademark for Novartis Ag’s anti-diabetic medication, Zomelis, for USD 13 million on 3rd December, 2019.

The vildagliptin based drug which is used to treat type 2 diabetes mellitus comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors.

The drug will start its commercialisation in Indian market from December 10, 2019, declared the company.

The company claims itself as one of the top 10 players in the anti-diabetes drugs segment in the Indian Pharmaceutical Market, referring to data by pharmaceutical market research company AIOCD-AWACS for October, 2019.

Eris Lifesciences focuses on chronic and acute categories of the Indian branded formulations market involving cardiovascular, anti–diabetes, vitamins, gastroenterology, gynaecology, IVF and CNS.

Straight Talk

View More